Nadia Mehsen-Cetre
Overview
Explore the profile of Nadia Mehsen-Cetre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perez-Castrillon J, Jodar-Gimeno E, Nociar J, Lojka M, Nikolov D, Cereto-Castro F, et al.
Nutrients
. 2025 Feb;
17(4).
PMID: 40005002
Given the crucial health benefits of vitamin D, addressing severe deficiencies is a pressing medical concern. This study aimed to evaluate the effectiveness and safety of two new weekly doses...
2.
Jodar-Gimeno E, Perez-Castrillon J, Nociar J, Lojka M, Nikolov D, Cereto-Castro F, et al.
Nutrients
. 2024 Nov;
16(22).
PMID: 39599585
Background/objective: Optimal vitamin D levels are required for bone health and proper functionality of the nervous, musculoskeletal and immune systems. The objective of this study was to assess the efficacy...
3.
Mancini M, Chapurlat R, Isidor B, Desjonqueres M, Couture G, Guggenbuhl P, et al.
Calcif Tissue Int
. 2024 Sep;
115(5):591-598.
PMID: 39316135
Osteoporosis is a skeletal disorder characterized by abnormal bone microarchitecture and low bone mineral density (BMD), responsible for an increased risk of fractures and skeletal fragility. It is a common...
4.
Bosco-Levy P, Briot K, Mehsen-Cetre N, OKelly J, Desamericq G, Abouelfath A, et al.
JBMR Plus
. 2023 Sep;
7(9):e10789.
PMID: 37701145
Although drugs for osteoporosis have been demonstrated to be effective in reducing fracture risk in placebo-controlled clinical trials, data on effectiveness in real-world practice is limited. Data from the French...
5.
Chapurlat R, Gensburger D, Trolliet C, Rouanet S, Mehsen-Cetre N, Orcel P
Bone
. 2022 Feb;
157:116343.
PMID: 35104665
Increased interleukin-6 (IL-6) has been observed in the bone tissue of fibrous dysplasia of bone/McCune-Albright syndrome (FD/MAS) and is possibly involved in the increased bone destruction and bone pain characterizing...
6.
Koumakis E, Cormier-Daire V, Dellal A, Debernardi M, Cortet B, Debiais F, et al.
Orphanet J Rare Dis
. 2022 Jan;
17(1):22.
PMID: 35090500
Background: Pregnancy and breastfeeding are associated with bone density loss. Fracture occurrence during pregnancy and post-partum, and its determinants, remain poorly known in Osteogenesis Imperfecta (OI). The aim of this...
7.
Gaujoux S, Pasmant E, Silve C, Mehsen-Cetre N, Coriat R, Rouquette A, et al.
Medicine (Baltimore)
. 2019 Dec;
98(50):e18102.
PMID: 31852070
Rationale: Intraductal papillary and mucinous neoplasms of the pancreas (IPMN) are preneoplastic lesions diagnosed with an increasing incidence. Recently, several groups have described, in up to 70% of IPMN, activating...
8.
Monsarrat P, Fernandez De Grado G, Constantin A, Willmann C, Nabet C, Sixou M, et al.
Joint Bone Spine
. 2019 Mar;
86(5):600-609.
PMID: 30822490
Objectives: To assess the effect of periodontal treatment on clinical and biochemical parameters of rheumatoid arthritis (RA) and quality of life (QoL) in patients with moderately active RA who were...
9.
Vinolas H, Grouthier V, Mehsen-Cetre N, Boisson A, Winzenrieth R, Schaeverbeke T, et al.
Clin Endocrinol (Oxf)
. 2018 May;
89(2):148-154.
PMID: 29781519
Objective: Osteoporotic fractures associated with Cushing's syndrome (CS) may occur despite normal bone mineral density (BMD). Few studies have described alterations in vertebral microarchitecture in glucocorticoid-treated patients and during CS....
10.
Scherlinger M, Germain V, Labadie C, Barnetche T, Truchetet M, Bannwarth B, et al.
Joint Bone Spine
. 2017 Nov;
85(5):561-567.
PMID: 29154920
Objective: To explore acceptance and retention rate of biosimilar CT-P13 after switching from originator infliximab (OI) in patients with various rheumatic diseases. Methods: Patients with stable rheumatoid arthritis (RA), ankylosing...